Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $48.3730 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Akebia Therapeutics Price Performance

Shares of NASDAQ:AKBA traded down $0.02 during midday trading on Friday, reaching $1.17. 941,067 shares of the company’s stock were exchanged, compared to its average volume of 3,341,941. The company’s 50 day simple moving average is $1.47 and its two-hundred day simple moving average is $2.20. The firm has a market capitalization of $309.16 million, a PE ratio of -16.64 and a beta of 0.38. Akebia Therapeutics has a 12 month low of $1.14 and a 12 month high of $4.08. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.80 and a current ratio of 1.94.

Wall Street Analysts Forecast Growth

AKBA has been the subject of several recent research reports. Piper Sandler dropped their price target on shares of Akebia Therapeutics from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. BTIG Research reissued a “buy” rating and issued a $5.00 target price on shares of Akebia Therapeutics in a report on Tuesday, December 2nd. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Akebia Therapeutics in a research report on Friday, February 6th. Wall Street Zen lowered Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Akebia Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.60.

Insiders Place Their Bets

In other Akebia Therapeutics news, CAO Richard C. Malabre sold 49,524 shares of Akebia Therapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.39, for a total value of $68,838.36. Following the completion of the transaction, the chief accounting officer owned 299,390 shares in the company, valued at approximately $416,152.10. The trade was a 14.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Akebia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Baird Financial Group Inc. lifted its position in Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,000 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Akebia Therapeutics by 13.1% during the first quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company’s stock worth $340,000 after purchasing an additional 20,499 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Akebia Therapeutics by 9.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 11,517 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Akebia Therapeutics by 171.8% during the first quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company’s stock valued at $5,231,000 after purchasing an additional 1,722,245 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Akebia Therapeutics by 123.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,652,746 shares of the biopharmaceutical company’s stock worth $6,016,000 after purchasing an additional 911,585 shares during the last quarter. 33.92% of the stock is currently owned by institutional investors and hedge funds.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.